COHANCE Cohance Lifesciences Q1 FY27 results (Apr–Jun 2026) and concall
Management summary
- Cohance Lifesciences reported a challenging Q1 FY27 with consolidated revenue declining 23% year-on-year and a low adjusted EBITDA margin of 2.2%, primarily due to shipment phasing, lower formulation revenue, and significant losses from NJ Bio.
- However, the company expects sequential improvement in Q2FY27 and a return to year-on-year growth in the second half.
- Restocking orders, new product launches, and operational normalization..
- The API+ business showed resilience, and Sapala demonstrated strong growth, while the Pashamylaram facility received 5 Form 483 observations from the USFDA
Source: Inve concall analysis and management guidance record.
Highlights
-
Sapala segment revenue grew 2.5x year-on-year to INR274 million.
-
API+ business remained resilient, exceeding internal expectations with favorable pricing and improved product mix.
-
Secured restocking orders for a commercial molecule, providing visibility for Q4 FY27 and FY28.
-
Completed customer audits across manufacturing sites without critical findings, reinforcing confidence in operating systems.
What they filed
Q1 FY27: revenue down 23.1%, net profit down 197.4% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|
| Revenue | 676 | 840 | 549 | 556 | 545 −19% | 619 −26% | 422 −23% |
| EBITDA | 237 | 229 | 112 | 121 | 95 −60% | 99 −57% | 1 −99% |
| Net profit | 153 | 117 | 46 | 66 | 29 −81% | 8 −93% | -45 −197% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Operational Outlook
Sequential Improvement Operational Outlook · Q2FY27 · High confidence improvement
Year-on-year Growth Operational Outlook · second half · High confidence return to year-on-year growth
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2Growth outlook for business segments (CDMO, API+, Specialty Chemicals) Partial
I actually see that in 3years or so that this business [nucleic acid] and whatever we have has a solid chance, in 3to 4years of almost doubling and growing significantly faster than this, right? Now that is directional.
Analyst sought specific growth ranges, but management provided qualitative, directional outlooks for each segment's potential over 3-5 years.
Asked by Kunal Dhamesha
Capital allocation priorities and synergies between business segments Direct
So, what we are prioritizing in terms of allocation of capacities, there is the Cohance hook. Where is it that we are better than the world? It could be, you know, areas like colored compounds, could be other areas where we believe we have positions, where we have historically do
Management clarified capital allocation is driven by ROI and strategic fit (innovation, value chain), not just segment size, and highlighted synergies in overheads and customer base.
Asked by Kunal Dhamesha
Unlock risks & concerns, Q2 FY27 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 11 risks, concerns & management red flags
- 5 watchlist triggers for Q2 FY27
- +8 more guidance targets & verbatim management quotes
- +6 more analyst Q&A exchanges & evasion checks
- Capital allocation & full section-by-section narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





